Market Cap: $1.09B
NT
Nektar Therapeutics
NKTR
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.09B
Nektar Therapeutics (Ticker: NKTR) is making significant strides in the development of novel therapies, as highlighted in their recent earnings call led by CEO Howard W. Robin. The company's ambitious…
Nektar Therapeutics Advances Promising Research Amid Legal Challenges Nektar Therapeutics is currently navigating a complex landscape as it further develops rezpegaldesleukin (REZPEG), its lead invest…
Nektar Therapeutics Faces Multiple Class Action Lawsuits Over Alleged Misrepresentation of Clinical Trial Data Nektar Therapeutics is currently embroiled in legal challenges as multiple law firms anno…
Nektar Therapeutics Faces Legal Challenges Over Clinical Trial Misconduct Allegations In recent developments, Nektar Therapeutics finds itself embroiled in multiple class action lawsuits alleging sign…
Growing Legal Challenges for Nektar Therapeutics Amid Trial Integrity Allegations Nektar Therapeutics faces significant legal challenges stemming from allegations related to its clinical trial process…
Nektar Therapeutics Faces Class Action Lawsuit Amidst Clinical Trial Developments Nektar Therapeutics finds itself embroiled in a class action lawsuit filed by Pomerantz LLP, representing investors wh…
Nektar Therapeutics Faces Class Action Lawsuits Over REZOLVE-AA Trial Allegations Nektar Therapeutics is currently embroiled in multiple class action lawsuits centered around its clinical trial for th…
Nektar Therapeutics Bolsters Talent Acquisition with Inducement Plan Nektar Therapeutics announces the granting of non-qualified stock options as part of its 2025 Inducement Plan, aimed at enhancing i…
### Nektar Therapeutics Expands Talent Pool with Strategic Equity Incentives On March 6, 2026, Nektar Therapeutics, a clinical-stage biotechnology company focused on innovative therapies for autoimmun…
Nektar Therapeutics Showcases Pipeline at Key Healthcare Events Nektar Therapeutics, a clinical-stage biotechnology firm based in San Francisco, is set to participate in two notable healthcare confere…
Nektar Therapeutics Engages in Key Industry Conferences to Highlight Pipeline Advances Nektar Therapeutics, a clinical-stage biotechnology company based in San Francisco, announces its participation i…
Nektar Therapeutics Takes Center Stage in Key Industry Events Nektar Therapeutics, a San Francisco-based biotechnology company, showcases its commitment to advancing treatments for autoimmune and chro…
Nektar closes $460 million offering to bolster pipeline and manufacturing Nektar Therapeutics announces the closing of an underwritten public offering that raises about $460 million in gross proceeds,…
Nektar Raises $400 Million to Advance Rezpegaldesleukin Phase 3 Program Nektar Therapeutics says it is raising about $400 million through an upsized underwritten public offering of common stock and, f…
Nektar posts sustained REZOLVE‑AD results at 52 weeks Durable efficacy of rezpegaldesleukin validates Treg strategy and guides Phase 3 Nektar Therapeutics is reporting 52‑week blinded maintenance data…
Rezpegaldesleukin shows durable control in REZOLVE‑AD, paving way for Phase 3 Nektar Therapeutics reports positive 52‑week results from its global REZOLVE‑AD Phase 2b study of rezpegaldesleukin, a reg…
Nektar posts positive 52‑week REZOLVE‑AD outcomes Rezpegaldesleukin delivers durable disease control and validates Treg approach Nektar Therapeutics reports sustained clinical benefit at 52 weeks from…
Nektar Therapeutics Faces Critical Crossroads Following Mixed Trial Results Nektar Therapeutics encounters a significant challenge as it evaluates the implications of the mixed topline results from it…
Nektar Therapeutics Faces Critical Crossroads Following Mixed Clinical Trial Results Nektar Therapeutics is currently navigating a significant juncture in its development pipeline following the mixed…
Nektar Therapeutics Advances in Alopecia Areata Treatment with Upcoming Investor Call Nektar Therapeutics, a clinical-stage biotechnology firm based in San Francisco, prepares for an important investo…
Nektar Therapeutics Prepares for Key Clinical Trial Update on Alopecia Areata Treatment Nektar Therapeutics, a clinical-stage biotechnology firm based in San Francisco, is gearing up for a significant…
Nektar Therapeutics Expands Talent Pool with New Equity Incentives Nektar Therapeutics, a clinical-stage biotechnology firm based in San Francisco, enhances its workforce by granting stock options to…
Nektar Therapeutics Expands Its Talent Pool with New Equity Incentives Nektar Therapeutics, a clinical-stage biotechnology firm based in San Francisco, takes significant steps to enhance its workforce…
Nektar Therapeutics: Navigating the Landscape of Therapeutic Innovations Nektar Therapeutics is at the forefront of developing innovative therapies that target unmet medical needs, particularly in the…
Nektar Therapeutics: Innovations in Immunotherapy and Pain Management Nektar Therapeutics continues to advance its position in the biopharmaceutical industry, focusing on innovative therapies for canc…